VIDEO05:00
Medical oncologist Steven M. Horwitz discusses the development and impact of three new, widely used therapies for T cell lymphoma: pralatrexate, romidepsin, and brentuximab vedotin.
{{{ _snippetResult.title.value }}}
{{{ _highlightResult.full_name.value }}}{{{ _highlightResult.degree.value }}}{{{ _highlightResult.doctor_type.value }}}
{{{ _snippetResult.lay_title.value }}}
{{{ _highlightResult.full_name.value }}}{{{ _highlightResult.job_title.value }}}
{{{ _highlightResult.query.value }}}